IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes
Jai Chand Patel, Jeremy Robbins, Michael Frenneaux, Adrienne. G. Siu et al.
Citations
1 citations
Journal
Circulation
Topics
Diabetes Treatment and Management
Field-Weighted Citation Impact (FWCI)
1.29
article
IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes
Jai Chand Patel, Jeremy Robbins, Michael Frenneaux, Adrienne. G. Siu, Sarah Birkhoelzer, Damian J. Tyler, Jack J. Miller, Moritz Hundertmark, Violet Matthews, Arash Yavari, John A. Henry, Oliver J. Rider, Ferenc E. Mózes, Paul Chamberlin, Rizwan Sarwar, Robert E. Gerszten, Clara Portwood, Prashant Rao, James T. Grist, Stefan Neubauer, Hakim‐Moulay Dehbi, Andrew Lewis, Ladislav Valkovič, Xu Shi, Shuning Zheng
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
CirculationVol. 153(8)
Institutions
Beth Israel Deaconess Medical Center (US), Aarhus University (DK), University Hospital of Bern (CH), Aarhus University Hospital (DK), John Radcliffe Hospital (GB), University of Oxford (GB), MRC Clinical Trials Unit at UCL (GB), Institute of Measurement Science of the Slovak Academy of Sciences (SK), NIHR Imperial Biomedical Research Centre (GB), Alexion Pharmaceuticals (United States) (US), Cancer Research UK Clinical Trials Unit (GB), Pediatrics and Genetics (US), Oxford University Hospitals NHS Trust (GB), Comprehensive Clinical Trials (US), University College London (GB), Imperial College London (GB), University of Birmingham (GB)